FiercePharma19m
Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M deal
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
FiercePharma1h
Fierce Pharma Asia—Merck's collabs with Daiichi, Eisai deliver readouts; Granules hit with FDA manufacturing observations
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
FiercePharma1h
Europe's CHMP turns down Apellis' pegcetacoplan appeal, endorses new drugs from Pfizer, ImmunoGen and Henlius
Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...
FiercePharma3h
In addressing inspection shortfall, FDA says it's gaining more inspectors than it's losing
In its effort to play catch up after thousands of factory inspections were delayed during the coronavirus pandemic, the FDA ...
FiercePharma2h
Recapping Digital Pharma East 2024
Fierce Pharma’s Andrea Park and Ben Adams talk about major trends from the event that came up in conversations, including the ...
FiercePharma19h
Gilead's Kite exits China cell therapy joint venture with Fosun Pharma
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
FiercePharma16h
Daiichi, AZ's first Enhertu DTC campaign kicks off during Thursday Night Football
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...